logo-loader
viewCanntab Therapeutics Ltd

Canntab Therapeutics thanks board director for valuable contributions

Ontario-based Canntab is developing advanced pharmaceutical-grade formulations of cannabinoids

1529065981_cannabis-plants.jpg
Canntab is developing advanced pharmaceutical-grade formulations of cannabinoids

Canntab Therapeutics Ltd (CSE:PILL) said Sheldon Inwentash had resigned from the board of directors to pursue other opportunities.

"I would like to thank Sheldon for his valuable contributions to the company, and, on behalf of the board, I wish him every success in his future endeavours," said Jeffrey Renwick, Canntab chief executive.

READ: Canntab Therapeutics merging medical cannabis with pharmaceutical expertise

Ontario-based Canntab is developing advanced pharmaceutical-grade formulations of cannabinoids.

It has in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained-release pharmaceutical dosages for therapeutic use.

It recently filed two additional Canadian patent applications, bolstering its intellectual property portfolio. Canntab's portfolio now includes 13 applications in Canada, the US and internationally.

Canntab is the first company to offer medical marijuana in pill form in Canada and possibly the rest of the world.

Quick facts: Canntab Therapeutics Ltd

Price: 0.48 CAD

CSE:PILL
Market: CSE
Market Cap: $12.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Canntab Therapeutics building cannabis delivery facility with FSD Pharma

Canntab Therapeutics Ltd (CSE:PILL) CEO Jeff Renwick and CFO Richard Goldstein tell Proactive Investor's Christine Corrado the cannabis delivery manufacturing company is lining up its ducks ahead of the legalization of cannabis in Canada on October 17 this year - as it announced a profit...

on 20/7/18

2 min read